Beta Thalassemia
Testing Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Beta thalassemia can be simplified as a diseased state of blood in which there is reduced
hemoglobin production. Hemoglobin is a protein containing iron and is present in Red blood
cells and the major function of hemoglobin is to carry oxygen to the body cells throughout
the body. Low hemoglobin content in the beta thalassemia patients usually leads to the lack
of oxygen in many parts of the body. Due to shortage of blood in the body patient, skin
becomes pale yellow and the other symptoms like weakness and fatigue are prominent. Risk
of abnormal blood clotting highly persist in the patients suffering from beta thalassemia.
According to the symptoms severity the disease can be classified into three thalassemia
major (Cooley's anemia), thalassemia intermediate and thalassemia minor. Amongst all the
forms of thalassemia, major is considered to be the most dreadful. Diagnostics tests
associated with Beta Thalassemia CBC Complete blood Count: CBC determines the amount of
hemoglobin and RBC in the blood. Carriers possess regular hemoglobin level but may have a
marginally reduced count of RBC. Patients having more severe type of thalassemia will have a
lower RBC and hemoglobin levels. The detection of the diseased state comprises of
measuring mean corpuscular volume which is the size of the RBC. Therefore the mean
corpuscular volume is usually found declining in the patients of thalassemia. Hemoglobin
tests will show a significant rise in A2 (>2.5%) and a fall in hemoglobin A (<97.5%) for beta
thalassemia. Further tests are needed to be performed in patients with decreasing RBC count
(anemia), to determine if thalassemia is the cause of the anemia. To rule out the possibility of
iron deficiency anemia iron levels in the blood are checked. DNA testing can also prove as an
effective technique for detecting mutation of gene that may cause beta, alpha, or delta
thalassemia and also DNA tests verify and confirms other tests, such as blood tests. Prenatal
Genetic testing Thalassemia in fetus can be detected by analyzing the amniotic fluids which is
Report
Description
Report Description
surrounding the fetus. Blood from the developing fetus can also be as good source of sample
for detecting thalassemia but aspirating blood sample may cause some damage to a
developing fetus, hence taking of amniotic fluid samples is generally preferred. Chorionic
Villus sampling (CVS) is another technique of diagnosing genetic problems in the fetus.
Sample is collected from the placental tissue or chorionic villus. There is risk of miscarriage
involved with every prenatal test. Preimplantation genetic diagnosis (PGD) is a new
procedure that may be performed on embryos which are produced by in vitro fertilization.
This test is performed on the embryos which are produced artificially and also allows parents
to carry and implant only those embryos that are not carrying the mutated thalassemia
genes.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/repgb-1738
Most commonly prone area for beta thalassemia are Mediterranean countries, African
countries, and Southeast Asian countries. Thalassemia trait almost affects 5% to 30% of the
population in these ethnic groups. The growing population in these countries act as the
drivers for beta thalassemia testing kit market. A number of factors such as high
implementation cost of sophisticated clinical and preclinical imaging systems, High cost of
maintenance, low life span of accessories used are restricting the growth of the global
imaging market.
Report
Description
Report Description
Based on technology, the beta thalassemia testing Market is segmented into the following:
• Perinatal Testing
• Complete Blood Count (CBC)
• DNA Testing
• Prenatal Testing
• Prenatal Genetic Testing
• Chorionic Villus sampling
• Preimplantation
Based on end user, the in vivo imaging systems market can be segmented into following:
•Hospitals
•Biotechnological Laboratories
•Diagnostic Laboratories
•Educational research institutes
•Pharmaceutical Industries
Based on geography, the in vivo Imaging Systems market is segmented into following:
•North America (U.S., Canada)
•Latin America (Mexico, Brazil)
Report
Description
Report Description
•Western Europe (Germany, Italy, U.K, Spain, France, Rest of Western Europe)
•Eastern Europe (Russia)
•Asia Pacific (China, India, ASEAN, Australia & New Zealand)
•Japan
•Middle East and Africa (GCC, S. Africa)
The testing market for beta thalassemia has a growing trend in the countries with ethnic
groups like, Mediterranean countries, African countries and few countries in Asia Pacific. As
migration has become more common, population of beta thalassemia can be seen rising in the
developed countries as well. There are several prenatal test available in the market to
determine the possibility of beta thalassemia including both invasive and noninvasive
technique. A recent advancement in the testing of beta thalassemia may determine the risk of
the disease by in vitro examination of the embryo. Even though there are many such testing
available in the market but lack of awareness leads to the negligence and delayed diagnosis of
the diseased state. Approximately 50k – 100k children with β-thalassemia major in middle and
low income countries die every year.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1738
The topical regions are more prone to possess high numbers of patients with beta thalassemia
like Nigeria, Sudan, Chad, Columbia etc. followed by few South Asian countries. Research
Institutes and Pharmaceutical companies, growing usage for beta thalassemia testing and
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705